cancer research

Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…

Immunotherapy has redefined cancer care—offering survival where little once existed, and in some cases, the possibility of long-term remission. But as its use expands across tumor types and earlier lines of treatment, a more complex reality is coming into focus:…

How policy, philanthropy, and scientific collaboration are reshaping the cancer research landscape and why early detection can be the difference between life and death. Twenty years ago, I received a diagnosis that changed everything and led me to dedicate the…

The conversation starts with a small detail that quickly becomes memorable. There is no coffee. On a podcast built around conversations over coffee, Professor Ricky Dylan Frazer, Consultant Medical Oncologist at Velindre Cancer Centre, Deputy CEO of the Immuno-Oncology Clinical…

If you try to list everything Charles Balch has done, you quickly realize the list does not help you understand the man. He has led some of the most important institutions in oncology. He has built systems that are now…

In oncology, progress is measured in survival rates, response curves, and treatment gains. But those numbers rest on a quieter assumption: that health systems can deliver what science makes possible. When they cannot, progress becomes uneven—not in discovery, but in…

25 Years of TKIs in CML: A Revolution and a Responsibility Twenty-five years ago, the arrival of imatinib changed the course of a disease and the lives of countless people diagnosed with it. Chronic myeloid leukemia (CML), once defined by…

From genetics to palliative care, clinician-scientist Rita Canário reflects on building a career in Oncology  that bridges research, patient care, and the human side of medicine and why this integration is essential for the future of oncology. “I was never…

In oncology, we are trained to deliver hope alongside difficult truths. We speak about survival rates, probabilities, and outcomes. In conflict settings, those terms lose stability. What does survival mean when hospitals are destroyed, treatments cannot reach patients, and people…

In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…